×
About 2,080 results

ALLMedicine™ Adrenocortical Carcinoma Center

Research & Reviews  757 results

Prognostic role of targeted methylation analysis in paraffin-embedded samples of adreno...
https://doi.org/10.1210/clinem/dgac470
The Journal of Clinical Endocrinology and Metabolism; Lippert J, Altieri B et. al.

Aug 6th, 2022 - Adrenocortical carcinoma (ACC) is a rare aggressive disease with heterogeneous prognosis. Previous studies identified hypermethylation in the promoter region of specific genes to be associated with poor clinical outcome. Comparative analysis of pr...

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04447014

Aug 5th, 2022 - Background: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75-90% and an average survival from the time of diagnosis o...

Transformed cells after senescence give rise to more severe tumor phenotypes than trans...
https://doi.org/10.1016/j.canlet.2022.215850
Cancer Letters; Palazzo A, Hernandez-Vargas H et. al.

Aug 5th, 2022 - Oncogenic stress-induced senescence initially inhibits tumor initiation by blocking proliferation and by attracting immune cells to clear potentially harmful cells. If these cells are not eliminated they may resume proliferation upon loss-of-tumor...

Key factors for effective mitotane therapy in children with adrenocortical carcinoma.
https://doi.org/10.1530/ERC-22-0146
Endocrine-related Cancer; Kuhlen M, Mier P et. al.

Jul 29th, 2022 - Adjuvant treatment with mitotane and chemotherapy is recommended for paediatric advanced and metastatic adrenocortical carcinoma (ACC). Yet, questions on the indication, dosage, and length of therapy are unanswered. Data from the German Paediatric...

Laparoscopic approach of pediatric adrenal tumors.
https://doi.org/10.1007/s00383-022-05188-x
Pediatric Surgery International; Oesterreich R, Varela MF et. al.

Jul 26th, 2022 - To analyze the role of laparoscopic surgery for the management of pediatric adrenal tumors (AT). Retrospective analysis of children diagnosed with AT, operated laparoscopically during 2003-2020. The strategy differed according to tumor extension. ...

see more →

Guidelines  3 results

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021,...
https://doi.org/10.6004/jnccn.2021.0001
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pal T et. al.

Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...

Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practi...
https://doi.org/10.1530/EJE-16-0467
European Journal of Endocrinology; Fassnacht M, Arlt W et. al.

Jul 9th, 2016 - : By definition, an adrenal incidentaloma is an asymptomatic adrenal mass detected on imaging not performed for suspected adrenal disease. In most cases, adrenal incidentalomas are nonfunctioning adrenocortical adenomas, but may also represent con...

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an end...
https://doi.org/10.1210/jc.2008-0104
The Journal of Clinical Endocrinology and Metabolism; Funder JW, Carey RM et. al.

Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...

see more →

Clinicaltrials.gov  45 results

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04447014

Aug 5th, 2022 - Background: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75-90% and an average survival from the time of diagnosis o...

Cabozantinib in Advanced Adrenocortical Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03612232

Jul 15th, 2022 - Adrenocortical carcinoma is an orphan malignant disease that has a dismal prognosis in advanced stages. Mitotane is the only approved treatment but is limited by severe toxicity. Efficacy of mitotane is unsatisfactory with an objective response ra...

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04358107

Jul 14th, 2022 - Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 mon...

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
https://clinicaltrials.gov/ct2/show/NCT05237934

Jul 7th, 2022 - Background: Neuroendocrine neoplasms (NENs) are divided into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These are rare malignancies occurring for example in the gastrointestinal tract, islets of the pancreas, lung, adrenal ...

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
https://clinicaltrials.gov/ct2/show/NCT04373265

Jun 30th, 2022 - Relacorilant is a small molecule antagonist of the glucocorticoid receptor (GR). The goal of this study is to assess the safety and efficacy of relacorilant when given in combination with pembrolizumab in patients with advanced adrenocortical carc...

see more →

News  25 results

Exceptional Responder Provides Treatment Clues in Bladder Cancer
https://www.onclive.com/view/exceptional-responder-provides-treatment-clues-in-bladder-cancer

Oct 6th, 2021 - Nikhil Wagle, MD An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient), according to r...

Neuroendocrine Tumors Clinical Practice Guidelines (NCCN, 2021)
https://www.medscape.com/viewarticle/959868

Sep 30th, 2021 - Updated clinical guidelines on the diagnosis and management of neuroendocrine and adrenal tumors were released in 2021 by the National Comprehensive Cancer Network (NCCN). The new version of the guidelines, published in the Journal of the National...

Advanced HCC: What's Next?
https://www.onclive.com/view/advanced-hcc-whats-next

Apr 2nd, 2021 - Transcript: Ghassan K. Abou-Alfa, MD: I would like to end our very valuable discussion here by asking each one of you about—all right, great, out of nothing we moved in the speed of light. I’m not sure even if there is any other disease that w...

Urine Screen as Part of Triple Test Improves ID of Adrenal Cancer
https://www.medscape.com/viewarticle/934790

Jul 29th, 2020 - A strategy that includes a urine steroid test along with imaging characteristics and tumor size criteria can significantly improve the challenging diagnosis of adrenocortical cancer, helping to avoid unnecessary, and often unsuccessful, further im...

Adrenocortical Carcinoma Clinical Practice Guidelines (2018)
https://reference.staging.medscape.com/viewarticle/904250

Nov 5th, 2018 - Clinical practice guidelines for the management of adrenocortical carcinoma in adults were released in October 2018 by the European Society of Endocrinology.[1] Diagnosis Perform a detailed hormonal workup of all patients with suspected adrenocort...

see more →

Patient Education  2 results see all →